Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil

GlobeNewswire May 8, 2019

Aquestive Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights

PR Newswire May 8, 2019

Aquestive Therapeutics Announces Daniel Barber Named to Chief Operating Officer

PR Newswire May 7, 2019

Aquestive Therapeutics to Announce First Quarter 2019 Financial Results and Recent Business Highlights on May 8, 2019

PR Newswire April 17, 2019

Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS

PR Newswire April 16, 2019

Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

PR Newswire March 25, 2019

Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

PR Newswire March 14, 2019

Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference

PR Newswire March 7, 2019

Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights on March 14, 2019

PR Newswire February 19, 2019

Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference

PR Newswire February 8, 2019

Aquestive Therapeutics Provides Update Regarding Suboxone® Sublingual Film Litigation

PR Newswire February 5, 2019

Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application

PR Newswire January 31, 2019

Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen

PR Newswire January 25, 2019

Aquestive Therapeutics Appoints Gary H. Slatko, M.D. as Chief Medical Officer

PR Newswire January 3, 2019

Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters

PR Newswire December 20, 2018

Aquestive Therapeutics Schedules Business Update Conference Call on December 20, 2018

PR Newswire December 18, 2018

Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

PR Newswire December 7, 2018

Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy

PR Newswire December 3, 2018

Aquestive Therapeutics Launches SYMPAZAN™ (clobazam) Oral Film with Widespread U.S. Availability

PR Newswire November 29, 2018

Market Trends Toward New Normal in Transcat, BioXcel Therapeutics, Youngevity International, Aquestive Therapeutics, TORM, and Transglobe Energy — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire November 21, 2018